G-CSF Biosimilars Approved By EU Could Impact Amgen Sales
This article was originally published in The Pink Sheet Daily
Executive Summary
Competitors to Amgen’s Neupogen and Neulasta soon could be joined by CT Arzneimittel’s proposed filgrastim product.
You may also be interested in...
Merck’s Ambitious Plans For Follow-On Biologics
Merck outlined ambitious plans for launching and growing a follow-on biologics business during its annual business briefing Dec. 9
Merck’s Ambitious Plans For Follow-On Biologics
Merck outlined ambitious plans for launching and growing a follow-on biologics business during its annual business briefing Dec. 9
Europe’s Biosimilars Ahead Of U.S., But Still Early
Beware confusion with generics, Biosimilars 2000 speakers warn.